Regeneron Pharmaceuticals, Inc. has announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited to acquire exclusive clinical development and commercial rights for a dual GLP-1/GIP receptor agonist, HS-20094, outside of the Chinese Mainland, Hong Kong, and Macau. Currently in Phase 3 testing, this therapeutic candidate has been studied in over 1,000 patients as a weekly subcutaneous injection, showing promising efficacy and safety data. The agreement includes an upfront payment of $80 million to Hansoh, with potential additional payments up to $1.93 billion based on achievement of development, regulatory, and sales milestones. Regeneron aims to integrate this candidate into its portfolio to address muscle loss and other obesity-related comorbidities.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。